PF-04958242 by Biogen/Pfizer for age-related hearing loss

Oral AMPA glutamate-receptor positive allosteric modulator evaluated for short-term effects on auditory function in age-related sensorineural hearing loss.

Verified as a real randomized, double-blind, placebo-controlled, single-dose crossover study of PF-04958242 in age-related sensorineural hearing loss. ClinicalTrials.gov lists Biogen as the current sponsor and states that the study was previously posted by Pfizer before sponsorship transferred to Biogen. The cited JAMA Otolaryngology paper reports the treatment was safe and well tolerated but did not demonstrate a significant change versus placebo on primary or secondary hearing endpoints, so HearScape should treat this as a historical completed AMPA-modulator hearing study rather than an active or efficacy-positive program.